|
Home:
Web Guide 2: David
J Kerr, MD, FRCP:
Select references
Selected references
Bismuth H, Adam R. Reduction of nonresectable liver metastasis
from colorectal cancer after oxaliplatin chemotherapy. Semin
Oncol 1998;25(2 Suppl 5):40-6. Abstract
Bismuth H et al. Resection of nonresectable liver metastases
from colorectal cancer after neoadjuvant chemotherapy. Ann
Surg 1996;224(4):509-20. Abstract
Chen MJ et al. Gene therapy for colorectal cancer: Therapeutic
potential. BioDrugs 2001;15(6):357-67. Abstract
Chung-Faye GA et al. In vivo gene therapy for colon cancer
using adenovirus-mediated transfer of the fusion gene cytosine deaminase
and uracil phosphoribosyltransferase. Gene Ther 2001;8(20):1547-
54. Abstract
Cunningham D et al. Optimizing the use of irinotecan in
colorectal cancer. Oncologist 2001;6 Suppl 4:17-23. Abstract
Delord JP et al. Dose escalation and pharmacokinetic study
of capecitabine (Xeloda) and irinotecan (CPT-11) in gastrointestinal
tumors: Preliminary results. Proc ASCO 2002;Abstract
397.
Djeha AH et al. Combined adenovirus-mediated nitroreductase
gene delivery and CB1954 treatment: A well-tolerated therapy for
established solid tumors. Mol Ther 2001;3(2):233-40. Abstract
Giacchetti S et al. Long-term survival of patients with
unresectable colorectal cancer liver metastases following infusional
chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
Ann Oncol 1999;10(6):663-9. Abstract
Hirawat S et al. Sequential irinotecan and capecitabine
(Xeloda) given every other week in the management of advanced metastatic
carcinoma: A phase I study. Proc ASCO 2002;Abstract
2127.
Jordan K et al. Randomized phase II trial of capecitabine
plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy
in advanced colorectal cancer (ACRC): Results of an interim analysis.
Proc ASCO 2002;Abstract
2225.
Kerr DJ. Capecitabine/irinotecan combination regimens
in colorectal cancer. Oncology (Huntingt) 2002;16(4 Suppl
3):27-9. Abstract
Kerr DJ et al. A phase I/II study of CPT-11 in combination
with capecitabine as first-line chemotherapy for metastatic colorectal
cancer (MCRC). Proc ASCO 2002;Abstract
643.
Kerr DJ et al. Gene-directed enzyme prodrug therapy for
cancer. Adv Drug Deliv Rev 1997;26(2-3):173- 184. Abstract
|
